MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the third quarter of 2006. For the three months ended September 30, 2006, Sepracor’s consolidated revenues were $289.3 million, of which revenues from pharmaceutical product sales were $280.1 million ($138.5 million for sales of XOPENEX® brand levalbuterol products and $141.6 million for sales of LUNESTA® brand eszopiclone).
